Innovator U.S. Equity Accelerated Plus ETF – July (BATS:XTJL – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totaling 286 shares, a decline of 34.6% from the September 30th total of 437 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 1,345 shares, the days-to-cover ratio is currently 0.2 days.
Institutional Trading of Innovator U.S. Equity Accelerated Plus ETF – July
A hedge fund recently bought a new stake in Innovator U.S. Equity Accelerated Plus ETF – July stock. Bullseye Investment Management LLC acquired a new stake in Innovator U.S. Equity Accelerated Plus ETF – July (BATS:XTJL – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,763 shares of the company’s stock, valued at approximately $114,000. Bullseye Investment Management LLC owned 0.85% of Innovator U.S. Equity Accelerated Plus ETF – July as of its most recent filing with the Securities & Exchange Commission.
Innovator U.S. Equity Accelerated Plus ETF – July Stock Performance
Shares of XTJL opened at $42.10 on Tuesday. The firm has a market cap of $13.68 million, a PE ratio of 23.92 and a beta of 0.78. Innovator U.S. Equity Accelerated Plus ETF – July has a 52-week low of $36.81 and a 52-week high of $43.15. The business’s 50 day moving average price is $42.52 and its two-hundred day moving average price is $40.79.
About Innovator U.S. Equity Accelerated Plus ETF – July
The Innovator U.S. Equity Accelerated Plus ETF – July (XTJL) is an exchange-traded fund that is based on the SPDR S&P 500 ETF Trust index. The fund aims for 3x upside return of SPY to a cap, with approximately single exposure on the downside, over a one-year outcome period. XTJL was launched on Jul 1, 2021 and is managed by Innovator.
See Also
- Five stocks we like better than Innovator U.S. Equity Accelerated Plus ETF – July
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for Innovator U.S. Equity Accelerated Plus ETF - July Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovator U.S. Equity Accelerated Plus ETF - July and related companies with MarketBeat.com's FREE daily email newsletter.
